Recruiting Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322 Conditions Adnexal Diseases, Advanced Breast Cancer, Breast Cancer, +30 more Locations START Los Angeles — Los Angeles, California, United States The University of Texas MD Anderson Cancer Center — Houston, Texas, United States NEXT Houston — Houston, Texas, United States NEXT San Antonio — San Antonio, Texas, United States View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521 Conditions Advanced Breast Cancer, Breast Cancer, Breast Diseases, +9 more Locations Banner MD Anderson Cancer Center — Gilbert, Arizona, United States Beverly Hills Cancer Center — Beverly Hills, California, United States City of Hope National Medical Center — Duarte, California, United States Cedars-Sinai Medical Center — Los Angeles, California, United States View all 211 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) NCT01881230 Conditions Breast Cancer, Breast Diseases, Breast Neoplasms, +15 more Locations Ironwood Cancer and Research Center — Chandler, Arizona, United States Arizona Center for Cancer Care — Glendale, Arizona, United States Arizona Cancer Research Alliance — Scottsdale, Arizona, United States Mayo Clinic Arizona — Scottsdale, Arizona, United States View all 140 locations View more locations Show fewer locations Loading locations... View Trial Details
